AbbVie posts KEEPsAKE 2 update; registers pediatric vitiligo and real-world MIRV studies

AbbVie's registry activity for the week centered on an update to a completed Phase 3 trial plus new postings in vitiligo, ovarian cancer, and lung cancer.

• KEEPsAKE 2 (NCT03671148), a Phase 3 double-blind trial of risankizumab versus placebo in active psoriatic arthritis, had its record last updated on October 28, 2026, with results first posted back on March 2, 2022. The trial enrolled 444 participants¹ and its primary outcome was the percentage of participants achieving an ACR20 response at Week 24, defined using tender and swollen joint counts along with other disease activity measures¹.
• AbbVie registered a Phase 3 trial of upadacitinib (NCT07896434) in pediatric patients with non-segmental vitiligo, listed as not yet recruiting with an estimated start of January 28, 2027. The study is designed to evaluate how effective, safe, and tolerable upadacitinib is for the treatment of non-segmental vitiligo in pediatric participants ages 6 to 11 years old², with approximately 154 pediatric participants enrolling at 110 sites worldwide².
• AbbVie also registered MIRELA (NCT07896421), an observational study of mirvetuximab soravtansine in platinum-resistant FRα-positive ovarian, fallopian tube, and peritoneal cancer, now listed as recruiting with an estimated start of October 21, 2026. The study aims to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine³, with approximately 500 participants to be enrolled at sites globally³.
• Two previously reported Phase 2 trials combining ABBV-706 with atezolizumab in first-line extensive stage-small cell lung cancer remain not yet recruiting. NCT07895043 pairs ABBV-706 with alveltamig and atezolizumab, with around 80 participants enrolling at approximately 25 sites worldwide⁴, and its primary outcome is objective response rate by Blinded Independent Central Review per RECIST v1.1, defined as a confirmed complete or partial response⁴. NCT07895056 pairs ABBV-706 with tarlatamab and atezolizumab, also enrolling around 80 participants at approximately 25 sites worldwide⁵, with the same BICR-based objective response rate endpoint defined as a best overall response of confirmed complete or partial response per RECIST version 1.1⁵.